Coologics raises $3m in oversubscribed seed round to develop drug-free vaginal infection treatments
Coologics, a clinical-stage medical device company, has successfully closed its Seed funding round, securing more than $3 million - significantly surpassing its initial target of $1.5 million.
The round was led by Prevail Ventures and Dream Ventures, and attracted key participation from two prominent university alumni networks: Ohio State’s Early Investor Network and Illinois Ventures’ Illini Angels Program. Coologics’ CEO and founder, Dr. Kim Langdon, is an Ohio State University alum, while Chief Medical Officer Dr. Nicole Williams hails from the University of Illinois.
Coologics’ flagship product is Vlisse, a novel drug-free treatment for vaginal infections. Vlisse is a tampon-like device designed to treat infections including vulvovaginal candidiasis (VVC), bacterial vaginosis, and mixed infections using a patented cooling mechanism.
This approach is a shift from traditional antifungal drugs, and focuses instead on restoring the vaginal environment to a healthy state without the use of traditional antibiotics or drugs. It also aims to minimize the risk of antibiotic resistance.
The funding round will support Coologics in its next major milestones, including the completion of its ongoing clinical trial, FDA submission, and the eventual market release of Vlisse.
"We are beyond excited about the investor commitment to Coologics," said Dr. Langdon, CEO/Founder.
"The overwhelming interest in our seed round validates the critical need for a more effective treatment for vaginal infections. We are thrilled to welcome our new investors and leverage their expertise to accelerate our growth and deliver impactful solutions to female patients and their clinicians."
Kerry Lawing, CEO of Prevail Ventures, emphasized the potential of Coologics’ approach.
"Dr. Langdon's vision and passion for this problem is what excited us the most about Coologics.”
"This market is ripe for innovative solutions like Vlisse. I look forward to watching our experienced teams at Prevail and Dream strategically support Coologics efforts in bringing Vlisse to market."